CFT7455, a next-generation IKZF1/3 degrader with favorable pharmacological properties in models of MM, has promoted its inclusion in a phase 1/2 study in relapsed/refractory (R/R) MM and Non-Hodgkin Lymphoma (NHL). This evidence concerns the gene IKZF1 and Miyoshi myopathy.